Associated Papers
Clinicopathological and molecular characterization of KRAS wild-type pancreatic ductal adenocarcinomas reveals precursor lesions with oncogenic mutations and fusions in RAS pathway genes.
Toriyama K et al.
The Journal of Pathology, 2025
40317966 (PubMed )
Supplement: PATH-266-337-s002.zip › path6432-sup-0002-TableS1S2S5-S7.xlsx › Table_S1
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
ARID1A Mutation from Targeted Next-Generation Sequencing Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer.
Lee SH et al.
Cancer Research and Treatment, 2023
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors.
Lee JK et al.
Npj Precision Oncology, 2022
36494601 (PubMed )
Supplement: 41698_2022_334_MOESM1_ESM.pdf
KRAS G12C mutations in Asia: a landscape analysis of 11,951 Chinese tumor samples.
Loong HH et al.
Translational Lung Cancer Research, 2020
Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival.
Amanam I et al.
Journal of Thoracic Disease, 2020
Comprehensive genomic profile of cholangiocarcinomas in China.
Tian W et al.
Oncology Letters, 2020
Select a paper to view details